{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:03:48Z","timestamp":1791515028688,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001169","name":"Cancer Council Tasmania","doi-asserted-by":"publisher","award":["RG20-07"],"award-info":[{"award-number":["RG20-07"]}],"id":[{"id":"10.13039\/501100001169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001169","name":"Cancer Council Tasmania","doi-asserted-by":"publisher","award":["PW18-03"],"award-info":[{"award-number":["PW18-03"]}],"id":[{"id":"10.13039\/501100001169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour de Cure","doi-asserted-by":"publisher","award":["RSP278-18\/19"],"award-info":[{"award-number":["RSP278-18\/19"]}],"id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008149","name":"Royal College of Pathologists of Australasia","doi-asserted-by":"publisher","award":["2021-2022"],"award-info":[{"award-number":["2021-2022"]}],"id":[{"id":"10.13039\/100008149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020480","name":"CSL Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1177305"],"award-info":[{"award-number":["1177305"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1169460"],"award-info":[{"award-number":["1169460"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jcyt.2024.01.011","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:46:51Z","timestamp":1707814011000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-4554","authenticated-orcid":false,"given":"Gerard J.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajini","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-7264","authenticated-orcid":false,"given":"Oliver","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Metierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Sagnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-1209","authenticated-orcid":false,"given":"Dannel","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Adelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-807X","authenticated-orcid":false,"given":"John E.J.","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.01.011_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040397","article-title":"Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors","volume":"9","author":"Weidemann","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0002","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s42003-020-01464-5","article-title":"Multiple proteases are involved in mesothelin shedding by cancer cells","volume":"3","author":"Liu","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0003","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1158\/0008-5472.CAN-11-0466","article-title":"Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0004","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0006","article-title":"Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0007","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0008","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-150834","article-title":"AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics","volume":"50","author":"Eketj\u00e4ll","year":"2016","journal-title":"Journal of Alzheimer's disease: JAD"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0009","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/jpet.103.059675","volume":"309","author":"Zhang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0163-7258(97)00023-5","article-title":"Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat","volume":"75","author":"Rasmussen","year":"1997","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0012","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0013","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0014","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jgm.803","article-title":"Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production","volume":"7","author":"Koldej","year":"2005","journal-title":"J Gene Med"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0016","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0017","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0018","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228015","article-title":"Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5","volume":"15","author":"Ando","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0020","unstructured":"Reddel RR, Yang K, Rhim JS, et al., inventors; US Department of Health and Human Services, assignee. Immortalized human bronchial epitherial mesothelial cell lines. US Patent 4885238A. 1989."},{"key":"10.1016\/j.jcyt.2024.01.011_bib0021","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1073\/pnas.82.11.3884","article-title":"Asbestos-associated chromosomal changes in human mesothelial cells","volume":"82","author":"Lechner","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0022","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0023","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0024","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","article-title":"A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity","volume":"8","author":"Feng","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0026","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0027","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/9872","article-title":"Improving antibody affinity by mimicking somatic hypermutation in vitro","volume":"17","author":"Chowdhury","year":"1999","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0028","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0029","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0031","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.abc1855","article-title":"T cell circuits that sense antigen density with an ultrasensitive threshold","volume":"371","author":"Hernandez-Lopez","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0032","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0033","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0034","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0035","doi-asserted-by":"crossref","first-page":"e43409","DOI":"10.1371\/journal.pone.0043409","article-title":"Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer","volume":"7","author":"Mezil","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.01.011_bib0036","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.humpath.2010.03.002","article-title":"Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter","volume":"41","author":"Tan","year":"2010","journal-title":"Hum Pathol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492400029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492400029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:36:27Z","timestamp":1778614587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492400029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S146532492400029X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.01.011","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}]}}